Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease, among other approved uses. MedsAcross supplies Eribulin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
HALAVEN is a microtubule inhibitor indicated for the treatment of patients with: Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.
Source: US FDA prescribing information
Eribulin inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into nonproductive aggregates. Eribulin exerts its effects via a tubulin-based antimitotic mechanism leading to G 2 /M cell-cycle block, disruption of mitotic spindles, and, ultimately, apoptotic cell death after prolonged mitotic blockage. In addition, eribulin treatment of human breast cancer cells caused changes in morphology and gene expression as well as decreased migration and invasiveness in vitro. In mouse xenograft models of human breast cancer, eribulin treatment was associated with increased vascular perfusion and permeability in the tumor cores, resulting in reduced tumor hypoxia, and changes in the expression of genes in tumor specimens associated with a change in phenotype.
Source: US FDA prescribing information
Administer 1.4 mg/m2 intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle. Reduce dose in patients with hepatic impairment or with moderate or severe renal impairment. Do not mix with other drugs or administer with dextrose-containing solutions.
Source: US FDA prescribing information
None. None
Source: US FDA prescribing information
Neutropenia: Monitor peripheral blood cell counts and adjust dose as appropriate. Peripheral Neuropathy: Monitor for signs of neuropathy. Manage with dose delay and adjustment. Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus and to use effective contraception. QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. Avoid in patients with congenital long QT syndrome.
Source: US FDA prescribing information
The most common adverse reactions (≥25%) in metastatic breast cancer were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation. The most common adverse reactions (≥25%) in liposarcoma and leiomyosarcoma were fatigue, nausea, alopecia, constipation, peripheral neuropathy, abdominal pain, and pyrexia. The most common (≥5%) Grade 3-4 laboratory abnormalities in liposarcoma and leiomyosarcoma were neutropenia, hypokalemia, and hypocalcemia.
Source: US FDA prescribing information
Effects of Other Drugs on HALAVEN No drug-drug interactions are expected with CYP3A4 inhibitors, CYP3A4 inducers or P-glycoprotein (P-gp) inhibitors. Clinically meaningful differences in exposure (AUC) were not observed in patients with advanced solid tumors when HALAVEN was administered with or without ketoconazole (a strong inhibitor of CYP3A4 and a P-gp inhibitor) and when HALAVEN was administered with or without rifampin (a CYP3A4 inducer).
Source: US FDA prescribing information
Store at 25°C (77°F), excursions permitted to 15° to 30° C (59° to 86° F). Do not freeze or refrigerate. Store the vials in their original cartons.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Eribulin, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Eribulin 1 mg/2 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Halaven 1 mg/2 mL injectionIntravenous | Eisai | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Eribulin in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 2 presentations of Eribulin and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Eribulin, including Halaven.
Yes. The US FDA first approved Eribulin on 15 November 2010, according to Drugs@FDA.
Yes. Eribulin has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Eribulin is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Eribulin is classified under ATC code L01XX41 (Eribulin).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.